Nutrition Product Combine With Continuous Glucose Monitoring in Gestational Diabetes Mellitus Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-15

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, multicenter, randomized controlled trial including about 60 Gestational Diabetes Mellitus patients (GDM) in Beijing will be included to evaluate the effectiveness and safety of nutrition product (SANZ®KINGWILL) in GDM patients, based on Continuous Glucose Monitoring (San MediTech CGM-303).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial

NCT01788527

Type 1 Diabetics Who Are Pregnant or Planning Pregnancy

COMPLETED NA

Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy

NCT05430204

Gestational Diabetes

COMPLETED NA

The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Type 2 Diabetes

NCT07097415

Continuous Glucose Monitoring Type 2 Diabetes (T2DM)

RECRUITING NA

Effects of Novel Flash Glucose Monitoring System on Glycemic Control in Adult Patients With Type 1 Diabetes Mellitus

NCT03522870

Diabetes Mellitus, Type 1

COMPLETED NA

Validating CGM for GDM

NCT06858787

Gestational Diabetes Mellitus (GDM)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will recruit pregnant women who were diagnosed as GDM by 75g Oral glucose tolerance test (OGTT) in 2nd trimester and followed up for 1month. A total of 60 GDM patients were expected to be enrolled. Using the double-blind method, they were randomly divided into two groups: experimental group and control group. Both of the two groups were provided medical nutrition treatment by nutritionist after GDM was diagnosed and CGM equipment (San MediTech CGM-303) was worn. Blood and urine samples were collected. At the following two days, oatmeal (SHIZHUANG) was used as extra meal at 10:00am and 15:00pm in both groups. In the next 4 weeks experimental group was provided with the domestic nutrition product (SANZ®KINGWILL), while existing products (GLUCERNA SR®) for control group as their extra meals at 10:00am and 15:00pm. In the last day, CGM equipment (San MediTech CGM-303) was removed and blood and urine samples were collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SANZ®KINGWILL Combined With CGM Equipment in GDM Patients GLUCERNA SR® Combined With CGM Equipment in GDM Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

SANZ®KINGWILL

Group Type EXPERIMENTAL

SANZ®KINGWILL

Intervention Type DIETARY_SUPPLEMENT

20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.

Control group

GLUCERNA SR®

Group Type OTHER

GLUCERNA SR®

Intervention Type DIETARY_SUPPLEMENT

17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SANZ®KINGWILL

20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.

Intervention Type DIETARY_SUPPLEMENT

GLUCERNA SR®

17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Women aged 22 to 40 years old 2. Diagnosed as gestational diabetes mellitus 3. Signed informed consent

Exclusion Criteria

* 1\. GDM patient who is no longer suitable to continue pregnancy. 2. Patients who use any hypoglycemic drugs or any type of similar products. 3. Patients who have diseases severely affected the nutrition product digestion and absorption.

4\. Patients with severe heart, liver, kidney dysfunction, mental retardation, dyscrasia, etc.

5\. Patients who cannot tolerate enteral nutrition. 6. Patients with other conditions which investigator believes they are not eligible for this study.

Minimum Eligible Age

22 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No